Skip Navigation

Center for Prevention of Progression of Blood Cancers Leadership

  • Robert Soiffer, MD

    Robert Soiffer, MD
    Co-Principal Investigator, Center for Prevention of Progression of Blood Cancers
    Chief, DF/BWCC Division of Hematologic Malignancies and Co-Chief, DF/BWCC Adult Stem Cell Transplantation Program
    Professor of Medicine, Harvard Medical School

    Dr. Soiffer graduated from New York University School of Medicine in 1983, and trained in internal medicine at Brigham and Women's Hospital, where he also was chief medical resident.

    He joined Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in 1988, after completing a medical oncology fellowship. Dr. Soiffer has served as vice president (2006), president (2007), and immediate past president (2008) of the American Society of Blood and Marrow Transplantation.

    Irene Ghobrial, MD

    Irene Ghobrial, MD
    Co-Principal Investigator, Center for Prevention of Progression of Blood Cancers
    Director, Michele & Stephen Kirsch Laboratory, Dana-Farber Cancer Institute
    Medical Oncologist, DF/BWCC Jerome Lipper Multiple Myeloma Center
    Associate Professor of Medicine, Harvard Medical School

    Dr. Ghobrial is a physician-scientist who specializes in early precursor conditions of multiple myeloma and Waldenström's Macroglobulinemia, specifically MGUS and smoldering diseases. Her research laboratory interests are in the area of cell trafficking and cell metastasis in B cell malignancies and the malignant bone marrow niches. She is the principal investigator of several clinical trials in both multiple myeloma and Waldenström's Macroglobulinemia.

    David Steensma, MD

    David P. Steensma, MD
    Co-Principal Investigator, Center for Prevention of Progression of Blood Cancers
    Medical Oncologist, DF/BWCC Adult Leukemia Program
    Associate Professor of Medicine, Harvard Medical School

    Dr. Steensma's primary area of clinical activity and research focus is the myelodysplastic syndromes (MDS) and related conditions. His research activity includes development of new therapies, as well as discovery of new somatic genetic mutations important in the pathobiology of this difficult and poorly-understood group of smoldering myeloid neoplasms.

    Dr. Steensma is also involved in collaborations with several laboratory-based scientists, particularly Benjamin Ebert, MD, PhD and Mark Fleming, MD, DPhil, to try to discover new pathways disturbed in MDS and related disorders – with the goal of finding pathways that can be exploited therapeutically.

    Benjamin Ebert, MD, PhD

    Benjamin Ebert, MD, PhD
    Co-Principal Investigator, Center for Prevention of Progression of Blood Cancers
    Medical Oncologist, DF/BWCC
    Assistant Professor of Medicine, Harvard Medical School

    Dr. Ebert's laboratory studies the biology and genetics of hematologic malignancies and other hematologic disorders. His group employs a range of genomic and proteomic technologies, as well as classical cellular and molecular biology approaches, to investigate the molecular basis of specific human diseases.

    Major focuses of the laboratory are myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Dr. Ebert identified a gene that plays a central role in the pathophysiology of MDS with deletions of chromosome 5q. These findings revealed a molecular link between del(5q) MDS and congenital bone marrow syndromes such as Diamond Blackfan anemia. The Ebert laboratory has also definied sets of mutations in MDS that are associated with various disease phenotypes, including overall survival and response to specific therapies.

    Investigators by Disease Group

    Monoclonal Gammopathy of Undermined Significance (MGUS) and Smoldering Multiple Myeloma

    Core leaders

    Irene Ghobrial, MD
    Jacob Laubach, MD
    Nikhil Munshi, MD
    Robert Schlossman, MD

    Other team members

    Kenneth Anderson, MD
    Claudia Paba-Prada, MD
    Paul Richardson, MD

    Immunoglobulin (Ig)M-MGUS and Smoldering Waldenström's Macroglobulinemia

    Core leaders

    Jorge Castillo, MD
    Irene Ghobrial, MD

    Other team members

    Steven Treon, MD, PhD

    Myelodysplastic Syndrome (MDS)

    Core leaders

    Benjamin Ebert, MD, PhD
    R. Coleman Lindsley, MD, PhD
    David Steensma, MD

    Other team members

    Daniel DeAngelo, MD, PhD
    Richard Stone, MD

    Myeloproliferative Neoplasms (MPN)

    Core leaders

    Ann Mullally, MD
    David Steensma, MD

    Other team members

    Martha Wadleigh, MD

    Monoclonal B Cell Lymphocytosis (MBL) and Early Chronic Lymphocytic Leukemia (CLL)

    Core leader

    Matthew Davids, MD

    Other team members

    Jennifer Brown, MD, PhD
    Catherine Wu, MD

    Low-Grade Lymphomas, including Early-Stage Follicular Lymphoma

    Core leader

    Ann LaCasce, MD

    Other team members

    Jennifer Brown, MD, PhD
    Arnold Freedman, MD
    Catherine Wu, MD

    Other Precursor Conditions or Clonal Genetic Abnormalities of the Bone Marrow/Blood

    Core leaders

    Benjamin Ebert, MD, PhD
    Aric Parnes, MD

    Other team members

    Nancy Berliner, MD